Sarepta Therapeutics
Sarepta Therapeutics Inc is an American biopharmaceutical company developing gene therapies and RNA-targeted therapeutics for rare neuromuscular diseases. The company commercializes specialized treatments for Duchenne muscular dystrophy, including micro-dystrophin gene therapy and exon-skipping therapeutics. Revenue is principally generated through commercial sales of its approved prescription gene therapies and RNA medicines to specialty distributors and health systems. Core end markets encompass pediatric neurology centers, neuromuscular disease clinics, and academic medical institutions globally. Sarepta Therapeutics holds a market-leading position in the development and commercialization of targeted RNA and gene therapies for Duchenne muscular dystrophy. The company is headquartered in Cambridge, Massachusetts, and its common stock trades on the Nasdaq Global Select Market.
5 of the funds FundTelligence covers report a position in Sarepta Therapeutics.
- Legal name
- Sarepta Therapeutics Inc
- Sector
- Health Care
- Country
- United States
- Funds holding it
- 5
- Exposure themes
- Gene Therapy, Genetic Medicine, Precision Medicine & Genomics
Funds holding Sarepta Therapeutics
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.18 % (full portfolio disclosed, October 2026)
- BlackRock iShares NASDAQ US Biotechnology UCITS ETF — BlackRock · 0.12 % (full portfolio disclosed, October 2026)
- Handelsbanken Global SMB Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, October 2026)
- DNB Global Enhanced Small Cap — DNB · 0.02 % (full portfolio disclosed, September 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)